Recent News

• 03.31.2026 - SCYNEXIS Announces $40.0 Million Private Placement
• 03.31.2026 - SCYNEXIS Announces $40.0 Million Private Placement
• 03.31.2026 - SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• 03.31.2026 - SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• 03.04.2026 - SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
• 03.04.2026 - SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
• 02.26.2026 - SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
• 02.26.2026 - SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
• 01.28.2026 - SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
• 01.21.2026 - SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247

Recent Filings

• 03.04.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.17.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.17.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.08.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors